BiotechTube

tividenofusp alfa

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis II

Conditions

Mucopolysaccharidosis II

Trial Timeline

Jul 16, 2020 → Feb 1, 2031

NCT ID
NCT04251026

About tividenofusp alfa

tividenofusp alfa is a phase 1/2 stage product being developed by Denali Therapeutics for Mucopolysaccharidosis II. The current trial status is active. This product is registered under clinical trial identifier NCT04251026. Target conditions include Mucopolysaccharidosis II.

What happened to similar drugs?

5 of 15 similar drugs in Mucopolysaccharidosis II were approved

Approved (5) Terminated (1) Active (10)
✅laronidaseSanofiApproved
✅LaronidaseSanofiApproved
✅Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
🔄Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
🔄rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
🔄Aldurazyme + Aldurazyme + placeboSanofiPhase 3
✅LaronidaseSanofiApproved

Hype Score Breakdown

Clinical
9
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06075537Phase 2/3Recruiting
NCT04251026Phase 1/2Active

Competing Products

20 competing products in Mucopolysaccharidosis II

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
29
anakinraSwedish Orphan BiovitrumPhase 1/2
32
laronidaseSanofiApproved
43
LaronidaseSanofiApproved
43
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
35
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
43
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
32
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
40
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
40
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
40
LaronidaseSanofiApproved
35
JR-141JCR PharmaceuticalsPhase 2/3
38
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
36
JR-446JCR PharmaceuticalsPhase 1/2
39
JR-171JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2
39
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
44
JR-141JCR PharmaceuticalsPhase 3
47
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 1/2
32